NEWSROOM
Press Releases by Agendia
News
Press Releases
Agendia Board of Directors Appoints Mark R. Straley as New CEO
IRVINE, CA and AMSTERDAM – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, today announced the appointment of veteran diagnostics industry leader Mark R. Straley as Chief Executive Officer. He succeeds Read More
NCCN Breast Cancer Guidelines Acknowledge MammaPrint’s Ability to Predict Prognosis
Respected Panel Cites RASTER, the Only Published Prospective Outcome Data of Its Kind, Which Demonstrates MammaPrint’s Ability to Identify Those Patients Who May Safely Forego Chemotherapy IRVINE, CA and AMSTERDAM, THE NETHERLANDS – Agendia, a Read More
Agendia Announces Recommendation of MammaPrint in Germany’s AGO Guidelines, at St. Gallen International Breast Cancer Conference
Company Also Highlights FDA Clearance of MammaPrint in FFPE IRVINE, CA and AMSTERDAM, THE NETHERLANDS – Agendia, a leading molecular diagnostics company that develops and markets genomic diagnostic products, announced at the St. Gallen International Read More
Agendia’s BluePrint Molecular Subtyping Assay Highlighted at the 32nd Annual Miami Breast Cancer Conference
Results of the NBRST Trial Using Agendia’s BluePrint 80-Gene Molecular Subtyping Assay Presented IRVINE, CA and AMSTERDAM, THE NETHERLANDS – Agendia, a leading molecular diagnostics company that develops and markets genomic diagnostic products, said new Read More
Agendia Receives New FDA Clearance for MammaPrint FFPE Breast Cancer Test
FDA Decision Covers Use of MammaPrint in FFPE for the 70-Gene Breast Cancer Recurrence Assay IRVINE, CA and AMSTERDAM, THE NETHERLANDS – Agendia, a leading molecular diagnostics company that develops and markets genomic diagnostic products, announced Read More
Agendia’s MammaPrint and BluePrint Tests to Be Highlighted at San Antonio Breast Cancer Symposium
Expert Symposium Panel Will Offer Insights Into How Functional Molecular Subtypes Can Better Individualize Treatment IRVINE, CA and AMSTERDAM, THE NETHERLANDS – New breast cancer research on Agendia’s MammaPrint® and BluePrint® genomic tests will be presented Read More
Agendia Breast Cancer Test for Molecular Subtyping Improves Match of Therapy to Patient, Study Finds
IRVINE, CA and AMSTERDAM – New data from an ongoing study indicates the BluePrint genomic test provides information about the molecular subtype of breast cancer that adds value beyond what can be learned from conventional IHC-FISH pathology testing. Read More